An NCI-designated Comprehensive Cancer Center
Joycelynne Palmer PhD

Joycelynne Palmer, Ph.D.

Biostatistician
Research Focus
  • Hematology & Hematopoietic Cell Transplantation
  • Clinical Trials Design
  • Translational Research
  • Precision Medicine
Appointments
Director, Division of Biostatistics; Research Professor, Division of Biostatistics, Department of Computational and Quantitative Medicine and the Hematologic Malignancies and Stem Cell Transplantation Institute

Research Teams

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008 Aug 1; 112(3):903-9. PubMed PMID: 18519812; PubMed Central PMCID: PMC2481551.
 
Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, Tsai NC, Senitzer D, Snyder DS, Thomas SH, Forman SJ. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009 Nov;15(11): 1407-14. PubMed PMID: 19822300; PubMed Central PMCID: PMC2795637.
 
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AV. Autologous transplantation for transformed non­Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. Biol Blood Marrow Transplant. 2014; 20(12): 2072-5. PMID: 25079874.
 
Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Annuals of Oncology. 2018; 29(3): 724-730. PMCID: PMC5889038.
 
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AV, Senitzer D, Forman SJ. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010 Feb 4;115(5):1098-105. PubMed PMID: 19965688; PubMed Central PMCID: PMC2817636.
 
Khaled SK, Palmer JM, Stiller T, Senitzer D, Maegawa R, Rodriguez R, Parker PM, Nademanee A, Cai JL, Snyder DS, Karanes C, Osorio E, Thomas SH, Forman SJ, Nakamura R. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated­donor PBSC transplant. Bone Marrow Transplantation. 2013 Feb;48(2):278-83. PubMed PMID: 23000644; PubMed Central PMCID: PMC3566319.
 
Ali H, Palmer J, Eroglu Z, Stiller T, Thomas SH, Kha led S, Shayani S, Parker P, Forman SJ, Nakamura R. Mycophenolate mofetl-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplantation. 2015; 50(2): 307-309. PubMed PMID: 25365064; PMCID: PMC4318766.
 
Kha led SK, Palmer JM, Herzog J, Stiller T, Tsai NC, Senitzer D, Liu X, Thomas SH, Shayani S, Weitzel J, Forman SJ, Nakamura R. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(2): 268-76. PubMed PMID: 26325438; PMCID PMC4716887.
 
Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Kha led S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed/refractory acute leukemia. Biol Blood Marrow Transplant 23(4): 618-624, 2017. PMCID: PMC5382014.
 
Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O'Donnell M, Stein AS, Marcucci G, Forman S, Pullarkat V. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology 92(9): 858-865, 2017. PMID: 28494518.
 
Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase 1/11 trial of the oral regimen ixazomib, Pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia, 2017. PMCID: PMC6005710
 
Caserta E, Chea J, Minnix M, Viola D, Vonderfecht S, Yazaki P, Crow D, Khalife J, Sanchez JF, Palmer JM, Hui S, Carlesso N, Keats J, Kim Y, Buettner R, Marcucci G, Rosen S, Shively J, Colcher D, Krishnan A, Pichiorri F. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 131(7): 741-745, 2018. PMCID: PMC5814935.
In The News